Board of Directors

E. James Hutchens

CEO, President, Director

Jim Hutchens is a proven entrepreneur with over 30 years of experience in general and marketing management in the medical technology industry. Mr. Hutchens served as a Managing Partner in Origin Partners, a $55 million early stage, venture capital fund and was the founder and CEO of both Microsurge Inc., a venture-backed, minimally invasive surgery company, and Choice Therapeutics, an advanced wound-care company which was sold to Alliqua Biomedical a NASDAQ list company. Mr. Hutchens also served in senior executive positions at Microvasive Endoscopy, a division of Boston Scientific, Smith & Nephew, and Millipore. He is a former member of the Board of Directors of the Brigham and Womens/ Faulkner Hospital and holds a BS in Business Administration from Boston University.

Ken Daignault


Ken Daignault has almost 30 years’ experience in the medical device field, with an emphasis in urology. Currently the Director of Gynecology Product Development at HOLOGIC in Massachusetts, Ken has held senior level management positions in major medical device companies, most recently with Boston Scientific as Director of R& D, Urology. He has also held positions at Kendall Healthcare (now Covidien) and CR Bard. Ken has been involved in all aspects of the medical device business, from product development and the design of protocols and procedures for bench and animal pre-clinical testing, to building long-term strategies for multiple-product portfolios at various stages of development.  Ken has strong relationships within the urology field and with key medical institutions, as well as a track record of bringing products from concept through successful product launch.

Robin A. Atlas, M.D.


Dr. Robin Atlas is Medical Director Emerita of Harvard Vanguard Medical Associates, the largest multi-specialty group practice in New England. Dr. Atlas maintained a primary care internal medicine practice at the flagship Kenmore Center for 20 years and served in many executive positions, including Chief of Internal Medicine for the Kenmore Office, Director of Medical Specialties and Deputy Medical Director, in which capacity she created the department of Utilization Management and Clinical Program Development for the Health Centers Division., Dr. Atlas became the Medical Director and Chief Medical Officer for the newly independent Harvard Vanguard Medical Associates and was recognized with the Chief Medical Officer Emerita designation upon her retirement in 2001. Dr. Atlas received her B.S. from the University of Illinois and her M.D. degree from Northwestern University Medical School. She interned and completed an internal medicine residency at Boston’s Beth Israel Hospital.

Kevin S. Slawin

Director, Lead Investor

Kevin Slawin, MD. is the Founder and Managing Partner of Rapha Capital Management, LLC. He is a successful and experienced oncologic and robotic surgeon, biotech consultant, investor, and founder focusing on disruptive technologies in oncology, T cells and immunotherapy, as well as other breakthrough healthcare technologies. He is the founder of Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) leading Bellicum to a successful $161 million IPO in December, 2014.

Chris Bleck


Mr. Bleck is an accomplished global healthcare industry veteran with over three decades of experience, including leading or being integrally involved with multiple clinical development programs, commercial product launches, public financings, licensing transactions, and mergers and acquisitions. Most recently, he served as the Chief Operating Officer for OvaScience, a life science company focused on the discovery and development of novel treatments for infertility. His earlier experience includes senior management roles with Cytyc Corporation (now Hologic, Inc.), Intact Medical Corporation (acquired by Medtronic plc) and Incept BioSystems, Inc. (acquired by ORIGIO a/s). Mr. Bleck began his career at Abbot Laboratories, where he held progressive positions over 18 years, including Corporate Vice President of Pediatric Products and President of Abbott Canada. Mr. Bleck holds a B.S. in Pharmacy and an M.B.A. from the University of Connecticut.